Global Top 10 Pharmaceutical Companies: Industry, Financial and SWOT Analysis

Introduction

This report forms a part of the Datamonitor's product series titled "Datamonitor Top 10 Industry Players". It aims to provide both quantitative and qualitative analysis to clients on the top 10 pharmaceutical companies' and pharmaceutical industry data and trends across pharmaceutical industry sector.

Scope

• Analyze the global top 10 pharmaceutical companies and the sector overall using key industry metrics and growth forecasts
• Assess the intensity of the competition using the Porter's five forces model, understand the major issues, and predict the key growth areas
• Investigate the top 10 players' SWOT, and access their five-year financial analysis
• Peruse descriptive profiles of the leading players, including details of the strategic initiatives undertaken in the last two years.

Highlights

• The global pharmaceuticals market generated total revenues of $644.2 billion in 2009, representing a compound annual growth rate (CAGR) of 4.3% for the period spanning 2005-09.
• The top 10 global pharmaceutical companies recorded revenues of $361.3 billion during 2009, an increase of 3.7% over 2008. The operating profit of these companies was $84.5 billion during 2009, an increase of 3.6% over 2008. The net profit was $81.3 billion in 2009, an increase of 25% over 2008.
• The average operating profit margin of the top 10 companies slightly declined to 23.2% in 2009 from the previous year's margin of 23.3%. In contrast, the average net profit margin grew to record 26.3% in 2009 as compared with 20.2% in 2008.

"
Reasons to Purchase

• Sector understanding: develop a detailed understanding of the pharmaceutical industry and identify its top 10 players
• Industry trends and behavior: find out the latest global trends driving the sector with an access to their five-year financial data
• Competitive landscape: obtain information on the sector's top-10 players and understand their key strengths, weaknesses, opportunities and threats

"

Contents

Table of Contents
FIGURES
Tables
Executive Summary
Industry analysis
Industry definition
Research highlights
Top 10 companies landscape
Market Value
Value
Market Forecast
Forecast
Market Segmentation: Product
Product
Market Segmentation: Geographic
Geographic
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Substitutes
Rivalry
Top 10 Companies Landscape
Overview
Pfizer
F. Hoffmann-La Roche
Novartis
GlaxoSmithKline
Sanofi-Aventis
AstraZeneca
Abbott Laboratories
Merck & Co.
Eli Lilly and Company
Bristol-Myers Squibb
Revenue analysis
Financial performance analysis
Operating profit analysis
Net profit analysis
Ratio analysis
Current ratio
Return on assets (ROA)
Debt equity ratio (D/E Ratio)
Inventory turnover ratio
Company Reports
Pfizer
Company overview
Business description
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Recent developments
F. Hoffmann-La Roche
Company overview
Business description
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Recent developments
Novartis
Company overview
Business description
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Recent developments
GlaxoSmithKline
Company overview
Business description
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Recent developments
Sanofi-Aventis
Company overview
Business description
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Recent developments
AstraZeneca
Company overview
Business description
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Recent developments
Abbott Laboratories
Company overview
Business description
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Recent developments
Merck & Co.
Company overview
Business description
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Recent developments
Eli Lilly and Company
Company overview
Business description
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Recent developments
Bristol-Myers Squibb Company
Company overview
Business description
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Recent developments
Five-Year Financial Information
Pfizer
F. Hoffman-La Roche
Novartis
GlaxoSmithKline
Sanofi-Aventis
AstraZeneca
Abbott Laboratories
Merck & Co.
Eli Lilly and Company
Bristol-Myers Squibb Company
Appendix
Methodology

LIST OF TABLES

Table 1: Global pharmaceutical market ($ billion), 2005-09
Table 2: Global pharmaceuticals market forecast ($ billion), 2009-14
Table 3: Global pharmaceuticals market segmentation: product (% share), 2009
Table 4: Global pharmaceuticals market segmentation: geography (% share), 2009
Table 5: Revenues and sales of global top 10 pharmaceutical companies ($m), FY2009
Table 6: Revenue growth of global top 10 pharmaceutical companies, FY2007-09
Table 7: Key financials of the global top 10 pharmaceutical companies, FY2009
Table 8: Key industry-specific ratios, FY2009
Table 9: Pfizer: financial and operational highlights, 2005-09 ($m)
Table 10: Pfizer: key industry-specific ratios, 2005-09
Table 11: F. Hoffman-La Roche: financial and operational highlights, 2005-09 ($m)
Table 12: F. Hoffman-La Roche: key industry-specific ratios, 2005-09
Table 13: Novartis: financial and operational highlights, 2005-09 ($m)
Table 14: Novartis: key industry-specific ratios, 2005-09
Table 15: GlaxoSmithKline: financial and operational highlights, 2005-09 ($m)
Table 16: GlaxoSmithKline: key industry-specific ratios, 2005-09
Table 17: Sanofi-Aventis: financial and operational highlights, 2005-09 ($m)
Table 18: Sanofi-Aventis: key industry-specific ratios, 2005-09
Table 19: AstraZeneca: financial and operational highlights, 2005-09 ($m)
Table 20: AstraZeneca: key industry-specific ratios, 2005-09
Table 21: Abbott Laboratories: financial and operational highlights, 2005-09 ($m)
Table 22: Abbott Laboratories: key industry-specific ratios, 2005-09
Table 23: Merck & Co.: financial and operational highlights, 2005-09 ($m)
Table 24: Merck & Co.: key industry-specific ratios, 2005-09
Table 25: Eli Lilly and Company: financial and operational highlights, 2005-09 ($m)
Table 26: Eli Lilly and Company: key industry-specific ratios, 2005-09
Table 27: Bristol-Myers Squibb Company: financial and operational highlights, 2005-09 ($m)
Table 28: Bristol-Myers Squibb Company: key industry-specific ratios, 2005-09

LIST OF FIGURES

Figure 1: Global pharmaceuticals market ($ billion), 2005-09
Figure 2: Global pharmaceuticals market forecast ($ billion), 2009-14
Figure 3: Global pharmaceuticals market segmentation: product (% share), 2009
Figure 4: Global pharmaceuticals market segmentation: geography (% share), 2009
Figure 5: Forces driving competition in the global pharmaceuticals market, 2009
Figure 6: Drivers of buyer power in the global pharmaceuticals market, 2009
Figure 7: Drivers of supplier power in the global pharmaceuticals market, 2009
Figure 8: Factors influencing the likelihood of new entrants in the global pharmaceuticals market, 2009
Figure 9: Factors influencing the threat of substitutes in the global pharmaceuticals market, 2009
Figure 10: Drivers of degree of rivalry in the global pharmaceuticals market, 2009
Figure 11: Revenues of global top 10 pharmaceutical companies ($m), FY2009
Figure 12: Revenue growth of the global top 10 pharmaceutical companies, FY2007-09
Figure 13: Operating performance analysis, FY2009
Figure 14: Net profit analysis, FY2009 Skip to top